BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
Express Scripts
Boehringer Ingelheim
Queensland Health
Covington
Teva
Federal Trade Commission
Cantor Fitzgerald
Julphar

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,110,940

« Back to Dashboard

Which drugs does patent 6,110,940 protect, and when does it expire?

Patent 6,110,940 protects RELPAX and is included in one NDA.

This patent has fifty-three patent family members in forty-one countries.
Summary for Patent: 6,110,940
Title: Salts of an anti-migraine indole derivative
Abstract:The present invention relates to hydrobromide salts of 3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole having the formula (I): ##STR1##
Inventor(s): Harding; Valerie Denise (Sandwich, GB), Macrae; Ross James (Sandwich, GB), Ogilvie; Ronald James (Sandwich, GB)
Assignee: Pfizer Inc. (New York, NY)
Application Number:08/776,680
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process; Formulation;

Drugs Protected by US Patent 6,110,940

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Ireland RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,110,940

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9417310Aug 27, 1994
PCT Information
PCT FiledMay 17, 1995PCT Application Number:PCT/EP95/01914
PCT Publication Date:March 07, 1996PCT Publication Number: WO96/06842

Non-Orange Book US Patents Family Members for Patent 6,110,940

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,380,226 Salts of an anti-migraine indole derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,110,940

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Finland 970800 ➤ Subscribe
Finland 113768 ➤ Subscribe
United Kingdom 9417310 ➤ Subscribe
Greece 3026475 ➤ Subscribe
Croatia P950460 ➤ Subscribe
Hungary T77310 ➤ Subscribe
Hungary 227822 ➤ Subscribe
Israel 115013 ➤ Subscribe
Spain 2112650 ➤ Subscribe
European Patent Office 0776323 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Queensland Health
Chinese Patent Office
Dow
US Department of Justice
Cipla
UBS
Baxter
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot